Gonadotropin releasing hormone antagonist
PreclinicalSmall molecule
Gonadotropin releasing hormone antagonist is one of 6 small molecule programs targeting Ovarian Stimulation. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Ovarian Stimulation
#DrugCompanyPhaseTrials
1Luveris
Merck & Co.Phase 3
Progestin
WWashington University School of Medicine
Phase 3
Depo-Provera
Eli LillyPreclinical
Gynorest
SSolvay Pharmaceuticals
Preclinical
Trelstar
OOncoVerity, Inc.
Preclinical
Gonadotropin releasing hormone antagonist
AAssiut University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oocyte1 trial
Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality
Unknown status·—·Phase 2/3·NCT03139474·120 enrolled
Ovarian Stimulation1 trial
Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles
Completed·—·N/A·NCT05767086·297 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAssiut University